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 Abstract
Aim: The evaluation of the influence of continuous transdermal estradiol supplementation combined with oral 
medroxyprogesterone on the somatotropic axis in postmenopausal women.
Material and methods: 25 women completed the study. Group A – 13 women received transdermal 17β-estradiol 
(Oesclim 50 - Fournier-Solvay) combined with oral 5 mg daily medroxyprogesterone (Gestomikron - Adamed). 
Group B - 12 women without treatment. Basic plasma FSH, estradiol, glucose, insulin, SHBG, hGH, total and free 
IGF-I, IGFBP-1 as well as IGFBP-3 were measured initially and at the 12th and 24th week of the study.
Results: The mean plasma FSH level was reduced and mean plasma estradiol level was increased in group A 
during estradiol supplementation. Mean plasma level of free IGF-I and free to total IGF-I ratio were increased in 
group A during 24 weeks of hormone therapy. In the control group (group B) there was the significant increase in 
mean plasma IGFBP-3 level. Other parameters showed no significant changes in the control group. 
Conclusion: The administration of transdermal 17β-estradiol combined with oral medroxyprogesterone increases 
the IGF-I bioavailability. However this influence do not exceed the physiologial level of IGF-I bioavailability. 
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Introduction
Circulating	 insulin-like	 growth	 factor-I	 (IGF-I)	 is	 mainly	
produced	 by	 the	 liver	 under	GH	 stimulation	 and	 is	 influenced	
by	 nutrition	 and	 insulin.	 IGF-I	 bioavailability	 is	 regulated	 by	
interactions	 with	 specific	 binding	 proteins	 (IGFBPs)	 [1].	 The	
somatotropic	 axis	 is	 also	 affected	 by	 hormonal	 milieu	 [2,	 3].	
A	number	of	experiments	 indicate	that	sex	steroids	exert	either	
stimulatory	or	inhibitory	action	on	the	somatotropic	axis	[3,	4].	
Evidence that estradiol is involved in the regulation of human 
Growth	Hormone	(hGH)	-	Insulin-like	Growth	Factor-I	(IGF-I)	-	
Insulin-like	Growth	Factor	Binding	Protein-3	(IGFBP-3)	system	
is	provided	not	only	by	the	observation	that	mean	hGH	level	is	
higher	 in	women	 than	men	and	 that	 the	fall	 in	hGH	as	well	as	
IGF-I	levels	with	aging	is	correlated	with	estradiol	level	but	also	
by	the	fact	that	estradiol	has	a	direct	effect	on	IGF-I	synthesis	and	
release	independent	of	hGH.	Estradiol	plays	also	a	permissive	role	
in	pituitary	hGH	release	[5-7].	The	latter	role	of	estradiol	is	based	
in	its	influence	on	both	pituitary	increase	in	IGF-I	mRNA	as	well	
as	 on	 regulation	 of	 pituitary	 somatostatin	 concentration	 [8,9].	
Estrogens	and	IGF-I	have	synergistic	effect	on	cell	proliferation	
[10].	 IGF-I	 augments	 the	 function	 of	 estrogen	 receptor	 [10].	
Total	IGF-I	serum	level	correlated	directly	to	free	sex	hormones	
and	 inversely	 to	 SHBG	 level	 in	 postmenopausal	 women	 [11].	
Gunter	et	al	conducted	a	case	cohort	study	of	relation	between	
free	 IGF-I	and	endometrial	 cancer	based	on	data	 from	Women	
Health Initiative Study and found an inverse association between 
plasma	 level	of	 free	 IGF-I	 and	endometrial	 carcinoma	 [12].	 In	
another	study	of	the	same	group	of	WHI	postmenopausal	women	
they	found	a	positive	association	between	endogenous	estradiol	
level,	free	IGF-I	and	risk	of	colorectal	cancer	in	postmenopausal	
women	[13].	
IGF-I	is	also	regarded	as	auto/paracrine	mediator	of	estradiol	
action	 [14].	 Estradiol	 exerts	 different	 effects	 on	 serum	 IGF-1	
levels	depending	on	its	origin,	route	of	administration	and	dose	
[2].	 Different	 kinds	 of	 hormone	 therapy	 (HT)	 have	 different	
effect	on	the	IGF-I	system,	depending	on	route	of	administration,	
oestrogen	dose,	basal	IGF-I	values	and	type	of	progestin	[1].	Oral	
estrogens	 due	 to	 their	 hepatocellular	 effect	 decrease	 the	 liver	
IGF-I	synthesis	and	therefore	reduces	 its	circulating	level	[10].	
The	reduced	level	increases	mean	diurnal	serum	GH	level	through	
reduced	feedback	inhibition	[15].	The	progestins	endowed	with	
androgenic	 effects-the	 19-nortestosterone	 derivatives	 and,	
to	 a	 lesser	 extent,	 medroxyprogesterone	 acetate	 (MPA)-tend	
to	 reverse	 the	 IGF-I	 decrease	 induced	 by	 oral	 oestrogens	 [1,	
16].	 There	 are	 conflicting	 reports	 on	 the	 effect	 of	 transdermal	
17β-estradiol	administration	on	the	plasma	level	of	total	and	free	
IGF-I.	Cardim	et	al,	Stomati	et	al	and	Bellantoni	et	al	found	no	
effect	 of	 transdermal	 estradiol	 therapy	on	 the	 plasma	 levels	 of	
total	and	free	IGF-I	as	well	as	IGFBP-1	[17-19].	Weissberger	et	
al	 	 applied	 transdermal	 0.1	mg/24	 hours	 estradiol	 patches	 and	
restored	 estradiol	 plasma	 level	 to	midfollicular	 one	 [15].	 That	
resulted	in	increase	of	serum	total	IGF-I	level.	However,	neither	
oral	nor	transdermal	estrogen	administration	completely	reverses	
the	age	 related	 reductions	 in	 spontaneous	or	GHRH-stimulated	
GH	and	IGF-I	secretion	[19].
IGFBP-3	plasma	level	was	higher	in	postmenopausal	women	
compared	to	premenopausal	ones.	This	lowers	the	bioavailability	
of	 IGF-I	 in	 older	 females	 [20].	 Oral	 estrogen	 administration	
causes	 a	 two	 to	 three-fold	 increase	 in	 IGFBP-1	 levels	 and	
reduction	in	IGFBP-3	levels.	Androgenic	progestins	oppose	the	
IGFBP-1	increase	as	well	as	IGFBP-3	decrease	induced	by	oral	
oestrogens	[1,	16,	17].	The	transdermal	estradiol	administration	
reduced	the	plasma	level	of	IGFBP-3	in	postmenopausal	women	
older	than	62	years	of	age	[19].
In	 circulation	 most	 of	 IGF-I	 binds	 to	 IGFBP-3,	 that	
inhibits	 the	 action	 of	 IGF-I.	 The	 remaining	 free	 IGF-I	 can	
cross	 the	 endothelial	 barrier	 and	 interact	 with	 receptors.	 That	
is	why	measuring	free	IGF-I	is	more	useful	than	assessment	of	
total	 IGF-I	 in	 evaluation	of	proliferative	 influence	of	 IGF-I	on	
neoplastic	 lesions	 [21].	Data	 on	 the	 effect	 of	 estrogen	 therapy	
(ET)	and	different	progestins	on	the	level	of	free	IGF-I	are	scant	
and	inconsistent	[1].
 Streszczenie
Cel pracy: Celem pracy była ocena wpływu łącznej podaży 17β-estradiolu przezskórnie wraz z doustną podażą 
octanu medroksyprogesteronu na stężenia hormonów osi somatotropowej u kobiet po menopauzie.
Materiał i metody: 25 kobiet wyraziło zgodę i ukończyło badanie. Grupa A - 13 kobiet, które otrzymywały 
przezskórnie 17β-estradiol (Oesclim 50 - Fournier-Solvay) wraz z doustną podażą 5 mg octanu medroksyprogesteronu 
dziennie (Gestomikron - Adamed). Grupa B - 12 kobiet, które nie otrzymywały suplementacji hormonalnej. W chwili 
rozpoczęcia badania, 12 i 24 tygodniu jego trwania dokonano pomiarów w surowicy w warunkach podstawowych 
stężeń FSH, estradiolu, glukozy, insuliny, SHBG, hGH, całkowitego i wolnego IGF-I, IGFBP-1 oraz IGFBP-3.
Wyniki: W trakcie stosowania łącznej ciągłej podaży estradiolu i octanu medroksyprogesteronu w grupie A 
stwierdzono spadek stężenia FSH i wzrost stężenia estradiolu. Po 24 tygodniach suplementacji hormonalnej 
doszło do wzrostu stężenia w surowicy  wolnego IGF-I oraz wskaźnika wolnego do całkowitego IGF-I. W grupie B 
(kontrolnej) obserwowano istotny statystycznie wzrost stężenia IGFBP-3. Stężenia pozostałych parametrów w tej 
grupie nie uległy istotnym statystycznie zmianom.
Wniosek: Zastosowanie łącznej podaży przezskórnej 17β-estradiolu wraz z doustną podażą octanu 
medroksyprogesteronu doprowadziło do wzrostu biodostępności IGF-I, jednakowoż wzrost ten nie przekroczył 
stężeń fizjologicznych
 Słowa kluczowe: estradiol / octan medroksyprogesteronu / hGH / IGF-I / IGFBP-3 / 
      / postmenopauza / 
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Aim
Therefore	 it	 seems	 interesting	 to	 evaluate	 the	 influence	 of	
continuous	 transdermal	 estradiol	 supplementation	 combined	
with	 oral	 medroxyprogesterone	 on	 the	 somatotropic	 axis	 in	
postmenopausal	women.
Material and methods
The	 study	 protocol	 was	 approved	 by	 the	 Jagiellonian	
University	 Ethical	 Board.	 Thirty	 four	 postmenopausal	 (having	
plasma	 FSH>30U/l	 and	 17β-estradiol	 <50ng/l)	 were	 recruited	
for	the	study	and	gave	the	informed	consent	to	participate.	None	
of	 them	 had	 received	 any	 form	 of	 HT	 prior	 to	 the	 beginning	
of	 the	 study.	 Of	 34	 postmenopausal	 women	 assigned	 to	 both	
groups	(A	and	the	control	group)	the	study	was	completed	by	25	
participants	 (mean	age	51.4±6.5	years	 )	 (13	 in	group	A	and	12	
in	group	B).The	women	with	diabetes	mellitus,	thyroid	diseases	
and adrenal glands’ disorders as well  as with contraindication to 
hormone	replacement	therapy	were	excluded	by	careful	history	
taking	 and	 physical	 examination	 and	 evaluating	 the	 glucose	
fasting	level,	 thyroid	hormones,	pap	smear,	mammography	and	
plasma	 cortisol.	 Each	 woman	 become	 postmenopausal	 after	
45 yeas of age. The women were randomly assigned to one 
of	 the	 study	 groups.	Women	 of	 group	A	 (N=13)	 were	 treated	
with	 transdermal	 supplementation	 of	 17β-estradiol	 (Oesclim	
50,	 Fournier-Solvay)	 at	 a	 dose	 of	 0.05	mg/24	 hours	 combined	
with	oral	medroxyprogesterone	acetate	at	a	daily	dose	of	5	mg	
(Gestomikron	 -	 Adamed)	 as	 a	 continuous	 therapy.	 Group	 B	
(N=12)	consisted	of	women	who	did	not	 receive	HT	treatment	
(control	group).	The	patients	were	examined	before	the	treatment	
and	 twice	 during	 the	 period	 of	 24	 weeks	 of	 HT	 in	 12	 weeks	
intervals.	During	each	visit,	special	attention	was	paid	to	physical	
and	psychological	well-being	of	each	patient,	as	well	as	 to	 the	
characteristic	menopausal	symptoms.	Clinical	characteristics	of	
the	study	groups	is	presented	in	table	I.
The	basal,	 fasting	plasma	 total	 insulin-like	growth	 factor-I	
(IGF-I),	free	IGF-I,	insulin-like	growth	factor	binding	protein-1	
and	 3	 (IGFBP-1,	 IGFBP-3),	 human	 growth	 hormone	 (hGH)	
glucose,	 insulin,	 estradiol,	 follicle	 stimulating	 hormone	 (FSH)	
and	 sex	 hormone	 binding	 globuline	 (SHBG)	 levels	 were	
measured	before	the	treatment	(examination	I)	and	after	12	weeks	
(examination	 II)	and	24	weeks	 (examination	 III)	of	HT.	At	 the	
same	 time	 intervals,	 all	 the	 parameters	 were	 measured	 in	 the	
control	group.	All	sample	tubes	were	kept	and	transported	in	the	
ice	box,	than	centrifuged	as	soon	as	possible	at	40C (refrigerated 
centrifuge,	Heraeus,	Germany).	Plasma	was	stored	frozen	at	–700C 
until the determination of the hormones, not later then after 3 
months	of	storage.	Frozen	samples	were	thawed	slowly	only	once	
and	 incubated	for	30	minutes	at	40C	prior	 the	analysis.	Plasma	
glucose	 level	 was	 determined	 on	 the	 day	 of	 blood	 sampling.	
Plasma	glucose	was	measured	by	the	enzymatic	method	(Vitros	
dry	chemistry	analyzer,	Johnson	and	Johnson).	Plasma	hormone	
levels were measured by using commercial Abbot MEIA kits 
(sensitivity:	1ng/ml	for	estradiolu	cross	reactivity	with	LH,	TSH,	
hCG	0,039%;	sensitivity	for	FSH	0.5mIU/ml	interference	5%	with	
bilirubin	 and	 hemoglobin,	 cross	 reactivity	with	 hCG	 0.016%).	
IGF-I	plasma	level	was	measured	by	RIA	Biosource	Europe	kits	
(sensitivity	 0.25ng/ml;	 intersample	 and	 interkit	 variability	was	
4.1%	and	9.3%	resp.;	cross	reactivity	with	insulin,	hGH	and	IGF-
II	0.001%,	0.01%	and	0.2%	resp.).	
Free	 IGF-I	 plasma	 levels	 were	 measured	 by	 means	 of	
DRG	 USA	 ELISA	 kits	 with	 sensitivity	 of	 0.015ng/ml	 and	 no	
cross	 reactivity	 with	 free	 IGF-II,	 insulin,	 IGFBP-1,	 IGFBP-3.	
IGFBP-1	 and	 IGFBP-3	 plasma	 levels	 were	 measured	 by	 RIA	
kits	(Diagnostic	System	Laboratories,	USA).	Sensitivity	for	both	
ones	was	0.5ng/ml	and	specifity	was	100%	for	IGFBP-1	and	99%	
for	IGFBP-3.	
Descriptive	 statistics,	 including	 mean	 values,	 median	 and	
SE, were calculated for all studied variables. The data obtained 
in	two	visits	/	groups	were	compared	by	means	of	Welch’s	t-test	
of	equality	of	expected	values	and	F-test	of	equality	of	variances.	
Significance	level	was	set	at	p<0.05.	Statistical	calculations	were	
performed	using	Statistica	3.1	software.
Results
At the beginning of the study there were no statistically 
significant	differences	between	group	A	and	B.	(Table	I).	
The	administration	of	continuous	transdermal	17β-estradiol	
combined	with	oral	medroxyprogesterone	reduced	the	mean	FSH	
level and increased mean estradiol level already after 12 weeks. 
This	change	remained	for	 the	next	12	weeks.	No	such	changes	
were	seen	in	the	control	group.	(Table	II).	Mean	plasma	level	of	
free	IGF-I	increased	after	12	weeks	of	HT.	The	increased	level	
of	free	IGF-I	remained	for	the	next	12	weeks	of	treatment.	This	
change	increased	also	the	free/total	IGF-I	ratio	after	12	weeks	of	
HT.	The	ratio	dropped	after	next	12	weeks	but	still	was	higher	than	
the	initial	value	(p<0.05).	The	mean	plasma	levels	of	IGFBP-3,	
IGFBP-1	 and	 total	 IGF-I	 as	 well	 as	 the	 IGFBP-3/IGF-I	 ratio	
were	not	influenced	by	the	HT.	However	in	the	control	group	the	
increase	in	the	mean	plasma	level	of	IGFBP-3	was	found	after	24	
weeks	of	observation.	(Table	III).	
Discussion
Our	study	showed	that	continuous	transdermal	administration	
of	 17β-estradiol	 combined	 with	 oral	 medroxyprogesterone	
increased	the	free	IGF-I	plasma	level	and	showed	no	influence	on	
mean	plasma	levels	of	total	IGF-I	and	IGFBP-1.	
Table I. The initial, clinical characteristics of patients with normal glucose 
metabolism who received transdermal 17β-estradiol supplementation combined  
with oral medroxyprogesterone (group A) and control group without treatment  
(group B). 
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The	 hormone	 therapy	 prevented	 the	 increase	 in	 plasma	
level	 of	 IGFBP-3.	 However	 it	 should	 be	 mentioned	 that	 the	
limited	number	 of	 patients	 included	 into	 the	 study	 reduces	 the	
strength of the conclusion. Stomati et al found no statistically 
significant	 change	 of	 plasma	 level	 of	 total	 IGF-I	 level	 during	
transdermal	 17β-estradiol	 administration	 combined	 with	 oral	
medroxyprogesterone	 [18].	 Stanosz	 et	 al	 in	 their	 recent	 study	
of	 75	 postmenopausal	 women	 with	 osteopenia	 found	 the	
increase	 in	 total	 IGF-I	 after	 12	weeks	 of	 transdermal	 estradiol	
therapy	 combined	 with	 progesterone	 given	 to	 subgroup	 of	 25	
women	 [22].	 Bellantoni	 et	 al	 apllied	 the	 transdermal	 estradiol	
supplementation	with	100µg	patches	for	6	weeks	and	also	found	
no	influence	on	plasma	IGF-I	levels	[19].	However	the	therapy	
reduced	the	IGFBP-3	plasma	level	[19].	Weissberger	et	al	used	
the	same	therapy	as	Bellantoni	group	but	observed	the	increase	
in	mean	total	IGF-I	level	[15].	Similar	results	were	obtained	by	
Słowinska-Srzednicka	 et	 al	 [23].	 Our	 results	 seem	 similar	 to	
those	 obtained	 by	 Cardim	 et	 al	 [17].	 They	 found	 the	 increase	
in	 plasma	 level	 of	 free	 IGF-I	 and	 no	 influence	 on	 the	 plasma	
total	IGF-I	and	IGFBP-1	levels	during	six	cycles	of	transdermal	
estradiol	 administration	with	 norethisterone	 acetate	 [17].	Helle	
et	al	compared	plasma	levels	of	IGF-I,	free	IGF-I,	IGF	binding	
proteins	-1	and	-3	in	114	postmenopausal	and	39	premenopausal	
women	and	found	lower	levels	of	total	and	free	IGF-I	as	well	as	
higher	levels	of	IGFBP-3	in	postmenopausal	women	[20].	That	
finding	may	explain	the	increase	in	IGFBP-3	during	the	24	weeks	
of	observation	in	group	B.	
The	hormone	therapy	applied	in	our	study	increased	the	free	
to	total	IGF-I	ratio	from	0.82%±0.41	to	2.0%±0.6.	The	ratio	did	
not	exceed	that	found	by	Kawai	et	al	who	reported	the	free/total	
IGF-I	ratio	raging	from	0.95	to	2.02%[24].	However	Skjaerbaek	
et	 al	 reported	 lower	 free/total	 IGF-I	 ratio	 (0.66%±0.05%)	 than	
that	found	by	Kawai	et	al	[25].	
Conclusion 
The	 continuous	 transdermal	 17β-estradiol	 administration	
combined	 with	 oral	 medroxyprogesterone	 increased	 the	
bioavailability	of	plasma	IGF-I
Table II. The influence of transdermal 17β-estradiol supplementation combined with oral medroxyprogesterone (group A) on parameters of clinical characteristics  
compared to the influence of 6 months’ observation of the control group in patients with normal glucose metabolism. 
Table III. The influence of transdermal 17β-estradiol supplementation combined with oral medroxyprogesterone (group A) on parameters of hGH-IGF-I-IGFBP axis  
compared to the influence of 6 months’ observation of the control group in patients with normal glucose metabolism. 
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